The Anti-gastroesophageal Reflux Effect of Anvitra Gastric Suspension on Outpatients With Gastroesophageal Reflux Disease

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

August 29, 2024

Study Completion Date

December 30, 2024

Conditions
GERD (Heartburn, Regurgitation, and Dyspepsia) FrequencyGERD (Heartburn, Regurgitation, and Dyspepsia) Severity
Interventions
DIETARY_SUPPLEMENT

Anvitra Gastric Suspension

Anvitra Gastric Suspension is provided as a liquid oral preparation, designed with a pleasant flavor to ensure compliance in patients. The intervention involves administering 1 packet (15 ml) per dose three times daily, taken orally 30 minutes after meals, for a duration of 14 days. The supplement is intended to alleviate symptoms of GERD (heartburn, regurgitation, and dyspepsia). Anvitra Gastric Suspension has been widely used in clinical and community settings, with a favorable safety profile and reported effectiveness in GERD treament.

Trial Locations (2)

Unknown

Center for Clinical Trial and Bioequivalence Study, Haiphong

Center for Clinical Trial and Bioequivalence Study, Haiphong University of Medicine and Pharmacy, Haiphong

All Listed Sponsors
lead

Haiphong University of Medicine and Pharmacy

OTHER

NCT06889246 - The Anti-gastroesophageal Reflux Effect of Anvitra Gastric Suspension on Outpatients With Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter